Patients should be educated on gastrointestinal side effects at treatment initiation
That includes looking at all the angles of GLP-1 drugs, including their potential side effects and how effective they are when used for treatment or prevention of diabetes, obesity and other conditions. Challenges for employers and employees 91% increase in PMPM costs between 12 months prior to starting a GLP-1 compared to 12 months after 9 The average cost of GLP-1 drugs can exceed $1,000 per patient per month
Promoting glycogen breakdown: It encourages the conversion of stored glycogen into glucose, making energy readily available
This piece is written for researchers, clinicians, and scientifically literate readers who want an accurate map: what retatrutide is, why insulin resistance drives PCOS, what the compound has genuinely shown (and in whom), what the closest analog class GLP-1 receptor agonists has shown in actual PCOS trials, how much of any benefit is likely to be weight-mediated versus weight-independent, how it stacks up against the insulin-sensitizing tools PCOS guidelines already endorse, and where the safety and regulatory lines fall